Porcine bioprosthesis use for surgical treatment of
|
|
- Meredith Campbell
- 5 years ago
- Views:
Transcription
1 Fifteen-Year Clinical Experience With the Biocor Porcine Bioprostheses in the Mitral Position Kaan Kırali, MD, Mustafa Güler, MD, Altuğ Tuncer, MD, Bahadır Dağlar, MD, Gökhan İpek, MD, Ömer Işık, MD, and Cevat Yakut, MD Department of Cardiovascular Surgery, Koşuyolu Heart and Research Hospital, Istanbul, Turkey Background. Bioprosthetic valve use represents a crucial improvement in surgical treatment of mitral valve disease. The aim of this study is to determine the long-term durability of the Biocor porcine bioprosthetic mitral valve. Methods. Between 1985 and 1989, a total of 158 Biocor porcine bioprosthetic valves were placed in the mitral position, and long-term results of these patients were investigated retrospectively in Results. Thirty-day mortality was 4.4% (7 patients). Total follow-up was 1,499 patient-years. Actuarial survival was 83.66% 3% at 5 years, 77.78% 3.36% at 13 years (1.8% patient-year). Multivariate analysis demonstrated younger age, duration of implantation, congestive heart failure, and functional class to be significant predictors of late mortality. Actuarial freedom from valverelated mortality was 98.58% 1% at 15 years (0.13% patient-year). Actuarial freedom from structural valve deterioration was 95.49% 1.8% at 5 years, 70.2% 4.12% at 10 years, and 64.82% 5.34% at 13 years (2.6% patient-year). Actuarial freedom from structural valve deterioration-related reoperation was 98.43% 1.1% at 5 years, 89.15% 2.85% at 10 years, and 76.82% 7.91% at 14 years. Multivariate analysis showed younger age and duration of implantation to be significant predictors of structural valve deterioration and its related reoperation. Conclusions. By studying a 15-year time period, it is seen that this new generation porcine bioprosthetic valve should be considered an alternative for mechanical valves in selected patients. (Ann Thorac Surg 2001;71:811 5) 2001 by The Society of Thoracic Surgeons Porcine bioprosthesis use for surgical treatment of heart valve diseases represents an important improvement in cardiac surgery. More than 30 years have passed since the first implantation of a glutaraldehydetreated valvular bioprosthesis. The most important disadvantage of mechanical valves is the requirement of indefinite anticoagulation, which exposes patients to the risk of hemorrhagic or thromboembolic complications, whereas tissue valves have limited long-term durability because of fibrocalcification and fatigue-related leaflet disruption. However, despite the limited long-term durability, some advantages of bioprostheses merit use in selected patients [1]. Improvements in valve design and preservation of bioprosthetic valves to avoid thromboembolic complications and to lengthen durability, and new techniques for management of reoperation, may change current indications for selecting these valves [2]. The Biocor (Biocor Industria e Pesguisa Ltda, Belo Horizonte, MG, Brazil) prosthesis was developed in Brazil in 1982 [3]. The leaflets are mounted on a flexible stent made of an acetyl copolymer covered by a tubular Dacron (C.R. Bard, Haverhill, PA) fabric. The main improvements of the Biocor valve, which is fixed and preserved in Accepted for publication Oct 14, Address reprint requests to Dr Kırali, Koşuyolu Heart and Research Hospital, 81020, Kadıköy, Istanbul, Turkey; kosuyolu@ superonline.com. glutaraldehyde under resting conditions with a pressure less than 1 mm Hg (third generation), are particularly careful harvesting, tanning, and handling of the tissue. This new generation bioprosthesis has been in use more than 15 years, yet data regarding long-term results of this device are limited [4, 5]. In this study, 15-year long-term results of Biocor porcine bioprosthesis were investigated retrospectively. Material and Methods At Koşuyolu Heart and Research Hospital, isolated mitral valve replacement with a bioprosthetic artificial valve (Biocor) was used in 158 patients between January 1985 and Long-term results of these patients were investigated retrospectively in The preoperative features of the patients are given in Table 1. The etiology in young patients (85%) was rheumatic fever in childhood, and was degenerative changes in older patients (15%). No patient had undergone valve surgery before, and no concomitant cardiac procedures were performed at operation. The main indications for operation was functional incapacity or echocardiographic findings. The same operative technique was used in all patients under elective conditions; cold crystalloid cardioplegia was applied every 20 minutes in additional to topical cooling. After left atriotomy, the mitral valve was resected and a bioprosthetic valve was replaced using simple sutures (2-0 Dacron polyester) including four 2001 by The Society of Thoracic Surgeons /01/$20.00 Published by Elsevier Science Inc PII S (00)
2 812 KIRALİ ET AL Ann Thorac Surg BIOCOR IN THE MITRAL POSITION 2001;71:811 5 Table 1. Patient Data Variable Data (Patients [%]) Mean age (yr) (48 14) Sex Women 97 (61.4%) Men 61 (38.6%) ECG (preop/postop) Sinus 90 (57%)/85 (56.3%) Atrial fibrillation 68 (43%)/66 (43.7%) NYHA (preop/late postop) Class I 8 (5%)/58 (46.75%) Class II 66 (41.8%)/58 (46.75%) Class III 72 (45.5%)/8 (6.5%) Class IV 12 (7.7%)/0 Mitral valve pathology Stenosis 52 (33%) Insufficiency 47 (29.7%) Both 59 (37.3%) Mitral valve size ECG electrocardiogram; NYHA New York Heart Association. pledged sutures. Sixty-seven patients (42.4%) underwent left atrial thrombectomy and appendix ligation. Anticoagulation In the postoperative period, 150 mg/day acetyl salicylic acid and 2.5 mg/day warfarin sodium was started after extubation. Both drugs were discontinued in patients in sinus rhythm after 3 months, but warfarin sodium was given lifelong at 2.5 mg/day for patients with atrial fibrillation, enlarged left atrium, or a history of thromboembolism or cerebrovascular event. Definition The definitions of complications and methods of analysis were consistent with the guidelines issued by Edmunds and colleagues [6]. Results are presented as mean standard deviation. Multivariate proportional hazard regression analysis was used to assess risk factors as independent predictors of patient survival and structural valve deterioration (SVD). Survival curves were constructed using the Kaplan-Meier method. The log rank test for independent groups was used to test the significance of differences. Categorical variables were compared using the 2 test. A p value less than or equal to 0.05 was considered statistically significant for all comparisons. Follow-up Information on patients was provided by the patient or the patient s relatives, physicians, or hospital registry in Follow-up was 96.7% complete with 146 patients. Five patients were lost to follow-up. Total follow-up was 1,499 patient-years, with a mean of years (range, 1 to 15 years). Results Thirty-Day and Late Mortality The 30-day mortality was 4.4% with 7 patients and late mortality was 17.9% with 27 patients. Causes of 30-day and late mortality are listed in Table 2. Actuarial survival and freedom from mortality are listed in Table 3 (Fig 1). Multivariate analysis demonstrated younger age, duration of implantation, congestive heart failure, and functional class to be significant predictors of late mortality. Frequency of valve-related mortality (VRM) was lower than non-vrm ( p ) (Fig 2). Functional Class The patients had significant improvement of their functional capacity as compared to their preoperative status ( p 0.001) (Fig 3). Thromboembolism and Anticoagulant-Related Hemorrhage Thromboembolic events were observed in 9 patients and a bleeding complication due to anticoagulation therapy was found in 1 patient (Table 3). Transient ischemic attack occurred in 5 patients (3.3%), stroke in 2 (1.3%), and reversible ischemic neurologic deficit in 2 patients (1.3%). Only 1 patient who had a stroke died. The mean time interval from operation to an embolic event was years (range, 1 to 9 years). Structural Valve Deterioration Bioprosthetic valve deterioration was observed in 39 patients (Table 3). Sixteen patients (41%) were reoperated and the other 23 patients are being followed echocardiographically. Actuarial freedom from SVD and corrected ratios according to patient age are shown in Figure 4. For all patients, multivariate analysis demonstrated younger age and duration of implantation as significant predictors of SVD. Table 2. Causes of 30-Day and Late Mortality Causes No. of Patients (%) 30-day mortality 7 (4.4%) Heart failure 5 (3.2%) Bleeding 1 (0.6%) Cerebrovascular accident 1 (0.6%) Late mortality 27 (17.9%) Cardiac 13 (8.6%) Cardiomyopathy 7 (4.6%) Heart failure 4 (2.7%) Valve related 2 (1.3%) Prosthetic endocarditis 1 (0.65%) Stroke 1 (0.65%) Noncardiac 14 (9.3%)
3 Ann Thorac Surg KIRALİ ET AL 2001;71:811 5 BIOCOR IN THE MITRAL POSITION 813 Table 3. Late-Term Results Actuarial Freedom (%) Actual Freedom (%) % patientyear Patient 5-Year 10-Year 15-Year 5-Year 10-Year (%) Mortality (21.5) NVRM a (16.6) VRM a (1.3) SVD (25.8) Mild/ reop (15.2) Severe/ reop (10.6) NSVD (98.7) All reoperation (13.9) SVD related (10.6) Endocarditis (2) PVL (1.3) Thromboembolism (5.9) Endocarditis (3.3) Antico/hemo (0.66) a For survival; confidence interval 95%. Antico/hemo anticoagulant-related hemorrhage; NSVD nonstructural valve deterioration; NVRM nonvalve-related mortality; PVL paravulvular leak; reop do not require reoperation; reop require reoperation; SVD structural valve deterioration; VRM valve-related mortality. Nonstructural Valve Dysfunction Two patients had significant paravalvular leakage and they were reoperated (Table 3). Reoperation Reoperation was performed in 21 patients (Table 3). Reoperative mortality was 4.76%, with 1 patient reoperated because of endocarditis 4 years after his first operation. Actuarial freedom from reoperation was shown in Figure 5. For all patients, multivariate analysis showed younger age and duration of implantation to be significant factors that increased the probability of reoperation. The difference for actuarial freedom from reoperation between patients with SVD and non-svd was very significant ( p 0.001). Prosthetic Valve Endocarditis Prosthetic valve endocarditis was observed in 5 patients (Table 3). Three of them were reoperated and the other 2 patients were treated medically. Comment Porcine bioprostheses have provided patients with an excellent quality of life at a low risk of major thromboembolism, essential lack of thrombosis, and freedom from hemorrhagic events related to anticoagulation. Glutaraldehyde-preserved porcine bioprostheses were widely used and their long-term results are published [7 10]. At present, more durable bioprosthetic valves are produced by using anticalcification and antimicrobial technology [11, 12]. The most significant reason for bioprosthetic valve dysfunction is valve deterioration after 5 to 6 years that requires reoperation within 8 to 12 years [13, 14]. The pathologic features of SVD are most thoroughly documented by Schoen and Levy [15]. When the long-term results of various valves were analyzed, it was shown that hospital mortality was closely related to preoperative functional capacity. Early mortality was determined to be 6% to 12% [7, 8, 10, 16 18]. In comparison, groups replaced with mechanical or biological mitral valves, early mortality was 11.2% for mechanical valves and 6.6% for bioprosthetic valves [17]. Fig 1. Overall survival of all patients. The number in the upper box shows the total number of patients who have undergone mitral valve replacement with the Biocor valve between 1985 and 1989, and the number in the lower box shows 30-day mortality. Fig 2. Actuarial freedom from valve- and nonvalve-related mortality in the following period (p ).
4 814 KIRALİ ET AL Ann Thorac Surg BIOCOR IN THE MITRAL POSITION 2001;71:811 5 Fig 3. Pre- and postoperative functional capacity of patients. (NYHA New York Heart Association functional class). The early mortality of Biocor bioprostheses was 6.1% in the study by Vrandecic and coworkers [4] and 13% in the one by Myken and coworkers [5]. In our series, early mortality was 4.43% with 7 patients, and valve-related early mortality was zero. In addition, our late mortality rate was lower than in other studies [4, 5]. The reason may be that the patients preoperative functional capacity was better in our study, or that our patients did not have any additional cardiac disease and were younger. Overall survival for several types of first generation porcine bioprosthetic valves in the mitral position was found to be between 70% and 87% at 5 years, between 44% and 76% at 10 years, and between 23% and 65% at 15 years [8, 18, 19]. Overall survival for new generation bioprostheses were 55% and 57% at 10 years [5, 10]. Myken and coworkers [2] compared bioprosthetic and mechanical valves in their study and found that the actuarial survival was 65.5% versus 55.2% at 10 years. In our experience, we found cumulative survival to be 83.66% 3% at 5 years and 77.78% 3.36% at 13 years. The causes of long-term mortality were noncardiac factors in our study, contrary to other series. We believe that our patients condition (younger age, higher functional capacity) is the most important reason for this long-term survival. One of the most important criterion of prosthetic valves in long-term observation is actuarial freedom from VRM, which is reported in different series as between 88% and 98% at 5 years, and between 60% and 95% at 10 years [8, 16 19]. For new generation bioprostheses, the freedom from VRM was 97% at 8 years [4], and 89% at 9 years [12]. In our series, the actuarial freedom from VRM was 98.58% 1% at 15 years. Deterioration shows rapid advance and requires prompt reoperation. Knowledge of the average time to failure for a specific porcine valve is important when counseling patients about valve selection. Tissue valve use in elderly patients should be expanded because of a low incidence of SVD, slow rate of deterioration, and a low VRM risk, in contrast to the use of mechanical valves. Freedom from SVD of different types of bioprosthetic valves implanted in the mitral position is between 45% and 84% at 10 years, and between 21% and 45% at 15 years [8, 16 18]. This ratio is between 75% and 95% at 8 to 10 years for Biocor [4, 5, 10]. In our series, actuarial Fig 4. Actuarial freedom from structural valve deterioration (SVD) and freedom from structural valve deterioration in different age groups. freedom from SVD was 95.49% 1.8% at 5 years, 70.2% 4.12% at 10 years, and 64.82% 5.34% at 13 years. Myken and coworkers found freedom from SVD to be 61.1% 18.4% at 10 years for the under 50-year-old age group [5]. In the literature, the freedom from SVD for the under 50-year-old age group was determined to be 10% to 40% for a 15-year period [7, 8]. This ratio for patients older than 50 years changed to between 75% and 85% [5, 10]. When we analyzed the age groups, we observed that the reoperation ratio was significantly higher in the younger age group than in the older age group (Fig 4). Another factor in valve deterioration is the duration of implantation. Bioprosthetic abnormalities in terms of calcification and cusp rupture (or both) and their hemodynamic consequences develop gradually and permit selection of the optimum time for reoperation [9]. Bioprosthetic failure progresses slowly in most patients with a porcine valve, allowing elective reoperation, but, in a few patients, an emergency reoperation that carries a high mortality risk, may be necessary [20]. Late deterioration should not be a contraindication for the use of bioprostheses in adults because of improvements in reoperation and myocardial protection techniques. Although the rate of asymptomatic SVD is improved, reoperation can be performed without damage to the patient s cardiac functions [21]. Myken and coworkers determined freedom from reoperation to be 78.9% 9.2% at 10 years, and freedom from valve-related reoperation to be 85.3% 9.6% at 10 years [5]. More recent Fig 5. Actuarial freedom from reoperation.
5 Ann Thorac Surg KIRALİ ET AL 2001;71:811 5 BIOCOR IN THE MITRAL POSITION 815 results shows that Biocor porcine bioprosthetic valves need fewer deterioration-related reoperations and provide greater freedom from SVD-related reoperations than other porcine valves [8, 16, 18, 19]. In particular, improvement in surgical reoperation techniques reduce the mortality and morbidity rates of bioprosthetic dysfunction-related reoperations [22, 23]. Improved results of reoperation using bioprosthetic valves, as published in recent years, complements the reduced incidence of SVD and should broaden indications for using those valves [12, 22]. The reoperation mortality of dysfunctional bioprosthetic valves in the mitral position was 10% [5]. The mortality ratio in this study was 5.3% (1 patient) and is similar to the rate of early mortality for initial operations. We performed reoperation in a way to not hurt cardiac function or functional capacity. The absence of a stent is believed to reduce mechanical stress on valvular tissue and result in better valve durability; thus, a new generation of bioprostheses was produced [24]. Use of a stentless mitral valve has the potential to maintain valvuloventricular interaction and to preserve left ventricular function. This new generation valve is an option for reoperation. In conclusion, valve type for mitral replacement is the most significant factor affecting the patient s life after operation. Furthermore, factors like patient age, sociocultural situation, quality of life, VRM, and morbidity must be taken into account. Because the selected valve should not limit quality of life, valve durability is an important long-term concern. In addition, an earlier investigation found that geographic and socioeconomic parameters should be taken into account during selection of a valve [25]. In developing countries, factors such as lack of definitive solutions for health problems; rheumatic fever, and rheumatic heart valve disease; lack of follow-up; and a young prolific population desiring children should be considered. These considerations limit use of mechanical valves for replacing the mitral valve. Because of these factors in developing countries, valve repair, if it is possible, should be the first choice. Freedom from anticoagulant use or anticoagulant-related complications is an important advantage of bioprosthetic valves. Longterm results indicate that SVD is often nonfatal because of its slow progress, and patients have almost always a chance for reoperation, whereas mechanical valverelated complications are often fatal. Because mortality after reoperation is similar to that of the primary operation, we recommend a new generation bioprosthetic valve for the adult age group. References 1. Carabello BA, Crawford FA. Valvular heart disease. N Engl J Med 1997;337: Myken PSU, Caidahl K, Larsson P, Larsson S, Wallentin I, Berggren HE. Mechanical versus biological valve prosthesis: a ten-year comparison regarding function and quality of life. Ann Thorac Surg 1995;60:S Vrandecic MO, Gontijo FB, Rabelo S. Clinical experience with a new generation of porcine bioprostheses. In: Bodnar E, Yacoub M, eds. Bioprosthetic valves. New York: Yorke Medical Books, 1986: Vrandecic MO, Gontijo FB, Paula e Silva JA, et al. Clinical results with the Biocor porcine bioprosthesis. J Cardiovasc Surg (Torino) 1991;32: Myken PSU, Caidahl K, Larsson S, Berggren HE. 10-year experience with the Biocor porcine bioprosthesis in the mitral position. J Heart Valve Dis 1995;4: Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ann Thorac Surg 1996;62: Jamieson WRE, Burr LH, Munro AI, Miyagishima RT. Carpentier Edwards standard porcine bioprosthesis: a 21-year experience. Ann Thorac Surg 1998;66:S Fann JI, Miller DC, Moore KA, et al. Twenty-year clinical experience with porcine bioprostheses. Ann Thorac Surg 1996;62: Myken PS, Berggren HE, Larsson S, Roberts B, Wallentin I, Caidahl K. Long-term Doppler echocardiographic results of aortic or mitral valve replacement with Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg 1998;116: Jamieson WR, Lemieux MD, Sullivan JA, Munro AI, Metras J, Cartier PC. Medtronic intact porcine bioprosthesis: 10 years experience. Ann Thorac Surg 1998;66:S Abolhada A, Yu S, Oyarzun R, et al. Biocor No-React detoxification process: a superior anticalcification method for bioprostheses. Ann Thorac Surg 1996;62: Langanki D, Ogle MF, Cameron JD, Lirtzman RA, Schroeder RF, Mirsch MW. Evaluation of a novel bioprosthetic heart valve incorporating anticalcification and antimicrobial technology in a sheep model. J Heart Valve Dis 1998;7: Gong G, Seifter E, Lyman WD, Factor SM, Blau S, Frater RWM. Bioprosthetic cardiac valve degeneration: role of inflammatory and immune reactions. J Heart Valve Dis 1993;2: Deiwick M, Glasmacher B, Baba HA, et al. In vitro testing of bioprostheses: influence of mechanical stresses and lipids on calcification. Ann Thorac Surg 1998;66:S Schoen FJ, Levy RJ. Pathology of substitute heart valves: new concept and developments. J Card Surg 1994;9(Suppl 2): Neville PH, Aupart MR, Diemont FF, Sirinelli AL, Lemoine EM, Marchand MA. Carpentier Edwards pericardial bioprosthesis in aortic and mitral position: a 12-year experience. Ann Thorac Surg 1998;66:S Vitale N, Giannolo B, Nappi GA, et al. Long-term follow-up of different models of mechanical and biological mitral prostheses. Eur J Cardiothorac Surg 1995;9: Yamak B, Kener E, Kiziltepe U, Mavitas B, Tasdemir O, Beyazit K. Late results of mitral valve replacement with Carpentier Edwards high profile bioprosthesis in young adults. Eur J Cardiothorac Surg 1995;9: Glover DD, Landolfo KP, Cheruvu S, et al. Determinants of 15-year outcome with 1119 standard Carpentier-Edwards porcine valves. Ann Thorac Surg 1998;66:S Mazzucco A, Milano A, Mazzaro E, Bortolotti U. Reoperation in patients with a bioprosthesis in the mitral position: indications and early results. J Heart Valve Dis 1993;2: Antunes MJ. Reoperations on cardiac valves. In: Acar J, Bodnar E, eds. Textbook of acquired heart valve disease. London: ICR Publishers, 1995: Spaminato N, Gagliardi C, Pantaleo D, et al. Bioprosthetic replacement after bioprosthesis failure: a hazardous choice? Ann Thorac Surg 1998;66:S Tyers GFO, Jamieson WRE, Munro AI, et al. Reoperation in biological and mechanical valve populations: fate of the reoperative patient. Ann Thorac Surg 1995;60:S Morea M, De Paulis R, Galloni M, Gastaldi L, di Summa M. Mitral valve replacement with the Biocor stentless mitral valve: early results. J Heart Valve Dis 1994;3: Rabago G. Comparison of mechanical and biological prosthesis. In: Rabago G, Cooley DA, eds. Heart valve replacement. New York: Futura Publishing, 1988:
A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationCarpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years
Surgery for Acquired Cardiovascular Disease Carpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, Robert T. Miyagishima,
More informationBioprostheses are prone to continuous degeneration
Twenty-Year Experience With the St. Jude Medical Biocor Bioprosthesis in the Aortic Position Walter B. Eichinger, MD, Ina M. Hettich, MD, Daniel J. Ruzicka, MD, Klaus Holper, MD, Carolin Schricker, Sabine
More informationP have been used for mitral and aortic valve replacement
A -Year Comparison of Mitral Valve Replacement With Carpentier-Edwards and Hancock Porcine Bioprostheses P. Perier, MD, A. Deloche, MD, S. Chauvaud, MD, J. C. Chachques, MD, J. Relland, MD, J. N. Fabiani,
More informationSurgery for Acquired Cardiovascular Disease
Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement W. R. E. Jamieson, MD, O. von Lipinski, MD, R. T.
More informationDurability of Pericardial Versus Porcine Aortic Valves
Journal of the American College of Cardiology Vol. 44, No. 2, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.053
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationThe clinical experience reported in recent Western series has provided
Surgery for Acquired Cardiovascular Disease Yu et al Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease Hsi-Yu Yu, MD a Yi-Lwun Ho, MD b Shu-Hsun Chu, MD c Yih-Sharng
More informationDurability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado
More informationRead at the Twenty-fourth Annual Meeting of The Western Thoracic Surgical Association, Whistler, British Columbia, June 24-27, 1998.
STRUCTURAL VALVE DETERIORATION IN MITRAL REPLACEMENT SURGERY: COMPARISON OF CARPENTIER-EDWARDS SUPRA-ANNULAR PORCINE AND PERIMOUNT PERICARDIAL BIOPROSTHESES W. R. Eric Jamieson, MD a Michel A. Marchand,
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationLONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS
LONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS David S. Peterseim, MD Ye-Ying Cen, MA Srinivas Cheruvu, MHS Kevin Landolfo, MD Thomas M. Bashore, MD James E.
More informationPrimary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: Hancock I Vekus Carpentier-Edwards at 4- to 7-Years Follow-up
Primary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: A Hancock I Vekus Edwards at 4- to 7-Years Follow-up Francisco Nistal, M.D., Edurne Artifiano, M.D., and Ignacio Gallo,
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationCARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP
CARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP M. R. Aupart, MD P. H. Neville, MD S. Hammami, MD A. L. Sirineili, MD Y. A. Meurisse, MD M. A. Marchand, MD Objective: The
More informationNearly 40 years after the pioneering efforts of Starr and
Prognosis After Aortic Valve Replacement With a Bioprosthesis Predictions Based on Meta-Analysis and Microsimulation J.P.A. Puvimanasinghe, MBBS, MSc, MD; E.W. Steyerberg, PhD; J.J.M. Takkenberg, MD; M.J.C.
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationSt Jude Medical Epic porcine bioprosthesis: Results of the regulatory evaluation
Jamieson et al Acquired Cardiovascular Disease St Jude Medical Epic porcine bioprosthesis: Results of the regulatory evaluation W. R. Eric Jamieson, MD, a Clifton T. P. Lewis, MD, b Marc P. Sakwa, MD,
More informationMitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients
Mitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients Kazutomo Minami, MD, Armin Zittermann, PhD, Sebastian Schulte-Eistrup, MD, Heinrich Koertke, MD, and Reiner
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationP substitutes since the introduction of the Ionescu-
Mitroflow Pericardial Valve: Long-Term Durability Daniel Y. Loisance, MD, Jean-Philippe Mazzucotelli, MD, Patrick C. Bertrand, MD, Philippe H. Deleuze, MD, and Jean-Paul Cachera, MD Department of Surgical
More informationby Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D., L. H. Burr, M.D., R. T. Miyagishima, M.D.
Carpentier-Edwards Standard Porcine Bioprosthesis: Primary Tissue Failure (Structural Valve Deterioration) by Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D.,
More informationHemodynamic Performance of the Medtronic Mosaic Porcine Bioprosthesis Up to Ten Years
Hemodynamic Performance of the Medtronic Mosaic Porcine Bioprosthesis Up to Ten Years Friedrich-Christian Riess, MD, Ralf Bader, MD, Eva Cramer, MD, Lorenz Hansen, MD, Bèr Kleijnen, MS, Gunther Wahl, MD,
More informationControversy exists regarding which valve type is best
Treatment of Endocarditis With Valve Replacement: The Question of Tissue Versus Mechanical Prosthesis Marc R. Moon, MD, D. Craig Miller, MD, Kathleen A. Moore, BS, Phillip E. Oyer, MD, PhD, R. Scott Mitchell,
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationReoperations after primary aortic valve replacement
Third-Time Aortic Valve Replacement: Patient s and Operative Outcome Kasra Shaikhrezai, MD, MRCS, Giordano Tasca, MD, FETCS, Mohamed Amrani, PhD, FETCS, Gilles Dreyfus, MD, FETCS, and George Asimakopoulos,
More informationStandarized definition of bioprosthetic valve deterioration and failure
Translational aortic valve research. From biology to treatment Standarized definition of bioprosthetic valve deterioration and failure Anna Sonia Petronio, MD, FESC Head of Cardiac Catheterization Lab
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationThe CarboMedics bileaflet prosthetic heart was introduced
The CarboMedics Valve: Experience With 1,049 Implants José M. Bernal, MD, José M. Rabasa, MD, Francisco Gutierrez-Garcia, MD, Carlos Morales, MD, J. Francisco Nistal, MD, and José M. Revuelta, MD Department
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationIschemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications
Surgery for Acquired Cardiovascular Disease Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications Eugene A. Grossi, MD Judith D. Goldberg, ScD Angelo
More informationIntensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)
European Heart Journal Supplements () 3 (Supplement Q), Q39 Q43 Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA
More informationRetrospective clinical analysis of stented vs. stentless porcine aortic bioprostheses q
European Journal of Cardio-thoracic Surgery 18 (2000) 46±53 www.elsevier.com/locate/ejcts Retrospective clinical analysis of stented vs. stentless porcine aortic bioprostheses q Mario Vrandecic*, Fernando
More informationVery Long-Term Survival Implications of Heart Valve Replacement With Tissue Versus Mechanical Prostheses in Adults <60 Years of Age
Very Long-Term Survival Implications of Heart Valve Replacement With Versus Prostheses in Adults
More informationReconstruction of the intervalvular fibrous body during aortic and
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,
More informationLate failure of transcatheter heart valves: An open question
Late failure of transcatheter heart valves: An open question A comparison with surgically implanted bioprosthetic heart valves. A. Rashid The Cardiothoracic Centre Liverpool, UK. Conflict of Interest Statement
More informationThe advantages and disadvantages of mechanical valve prostheses and
Surgery for Acquired Cardiovascular Disease Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients Ye-Ying Cen, MA Donald D. Glower, MD Kevin Landolfo,
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationStentless aortic xenografts were introduced a decade
Survival After Stentless and Stented Xenograft Aortic Valve Replacement: A Concurrent, Controlled Trial Giovanni Battista Luciani, MD, Gianluca Casali, MD, Stefano Auriemma, MD, Francesco Santini, MD,
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationDepartment of Cardiac Surgery, Trousseau University Hospital, Tours, France
Risk Factors for Valve-Related Complications after Mechanical Heart Valve Replacement in 505 Patients with Long-Term Follow Up Thierry Bourguignon, Eric Bergöend, Alain Mirza, Grégoire Ayegnon, Paul Neville,
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationAspirin or Coumadin as the Drug of Choice
Aspirin or Coumadin as the Drug of Choice for Valve Replacement with Porcine Bioprosthesis L. Nufiez, M.D., M. Gil Aguado, M.D., D. Celemin, M.D., A. Iglesias, M.D., and J. L. Larrea, M.D. ABSTRACT Eight
More informationEleven years experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with long-term relative survival rate
European Journal of Cardio-thoracic Surgery 22 (2002) 912 921 www.elsevier.com/locate/ejcts Eleven years experience with the Biocor stentless aortic bioprosthesis: clinical and hemodynamic follow-up with
More informationAortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years experience in 130 patients
Aortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years experience in 130 patients Augusto D Onofrio, MD, Stefano Auriemma, MD, Paolo Magagna, MD, Alessandro Favaro, MD,
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationAORTIC VALVE REPLACEMENT WITH FREEHAND AUTOLOGOUS PERICARDIUM
AORTIC VALVE REPLACEMENT WITH FREEHAND AUTOLOGOUS PERICARDIUM Fifty-one patients with a mean age of 31.2 years underwent aortic valve replacement with glutaraldehyde-treated autologous pericardium. Pure
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationEight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis
Eight-Year Results of Aortic Root Replacement With the Freestyle Stentless Porcine Aortic Root Bioprosthesis Neal D. Kon, MD,* Robert D. Riley, MD, Sandy M. Adair, RN, Dalane W. Kitzman, MD, and A. Robert
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationA valve was initiated at the Medical University of
St. Jude Prosthesis for Aortic and Mitral Valve Replacement: A Ten-Year Experience John M. Kratz, MD, Fred A. Crawford, Jr, MD, Robert M. Sade, MD, Arthur J. Crumbley, MD, and Martha R. Stroud, MS Division
More informationRESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES
e-issn:2322-0139 RESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES Comparative Evaluation of Safety Outcomes of Different Prosthetic Valves in Indian Subjects. Kama Raval 1 *, Reena
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationBall Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation
Ball Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation Begonia Gometza, MD, and Carlos M. G. Duran, MD, PhD Department of Cardiovascular Diseases, King Faisal Specialist Hospital
More informationLong-Term Results With the Medtronic-Hall Valvular Prosthesis
Long-Term Results With the Medtronic-Hall Valvular Prosthesis Cary W. Akins, MD Cardiac Surgical Unit, Massachusetts General Hospital, Boston, Massachusetts Background. Although more than 170,000 Medtronic-
More informationIsolated Mitral Valve Replacement with the Hancock Bioprosthesis: A 13-Year Appraisal
Isolated Mitral Valve Replacement with the Hancock ioprosthesis: A 13-Year Appraisal Vincenzo Gallucci, M.D., berto ortolotti, M.D., Aldo Milano, M.D., Carlo Valfrk, M.D., Alessandro Mazzucco, M.D., and
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationTrifecta Valve. Clinical Compendium. Five Year Data
Trifecta Valve Clinical Compendium Five Year Data Trifecta Valve Compendium INTRODUCTION The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationMitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease
Mitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease Kenji Kuwaki, MD, PhD, Nobuyoshi Kawaharada, MD, PhD, Kiyofumi Morishita, MD, PhD, Tetsuya Koyanagi,
More informationPrognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding hazards
European Heart Journal Supplements (1) 3 (Supplement Q), Q27 Q32 Prognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding
More informationMitroflow Aortic Bioprosthesis 5-Year Follow-Up: North American Prospective Multicenter Study
Mitroflow Aortic Bioprosthesis 5-Year Follow-Up: North American Prospective Multicenter Study Federico M. Asch, MD, David Heimansohn, MD, Daniel Doyle, MD, Walter Dembitsky, MD, Francis D. Ferdinand, MD,
More informationThe operative mortality associated with repeat heart valve surgery is. Repeat heart valve surgery: Risk factors for operative mortality
Surgery for Acquired Cardiovascular Disease Repeat heart valve surgery: Risk factors for operative mortality J. Mark Jones, MA, AFRCS a Hugh O Kane, MCh, FRCS a Dennis J. Gladstone, FRCS a Mazin A. I.
More informationTwenty-year experience with the St Jude Medical mechanical valve prosthesis
Surgery for Acquired Cardiovascular Disease Ikonomidis et al Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S. Ikonomidis, MD, PhD John M. Kratz, MD Arthur J. Crumbley
More informationVALVE REPAIR VERSUS REPLACEMENT FOR MITRAL INSUFFICIENCY: WHEN IS A MECHANICAL VALVE STILL INDICATED?
VALVE REPAIR VERSUS REPLACEMENT FOR MITRAL INSUFFICIENCY: WHEN IS A MECHANICAL VALVE STILL INDICATED? Eugene A. Grossi, MD Aubrey C. Galloway, MD Jeffrey S. Miller, MD Greg H. Ribakove, MD Alfred T. Culliford,
More informationIndications and Late Results of Aortic Valve Repair
Indications and Late Results of Aortic Valve Repair Prof. Gebrine El Khoury Department of Cardiovascular and Thoracic Surgery Cliniques St. Luc Brussels, Belgium Aortic Valve Repair Question # 1 Can the
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationNineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up
Nineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up Dilip Sawant, FRCS, Arun K. Singh, MD, William C. Feng, MD, Arthur A. Bert, MD, and Fred Rotenberg, MD
More informationChoice of Prosthetic Heart Valve in Adults
Journal of the American College of Cardiology Vol. 55, No. 22, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.085
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationThe use of mitral valve (MV) repair to correct mitral
Outcomes and Long-Term Survival for Patients Undergoing Repair Versus Effect of Age and Concomitant Coronary Artery Bypass Grafting Vinod H. Thourani, MD; William S. Weintraub, MD; Robert A. Guyton, MD;
More informationPATIENT BOOKLET MEDTRONIC SURGICAL VALVE REPLACEMENT. Tissue Valve for Aortic and Mitral Valve Replacement
PATIENT BOOKLET MEDTRONIC SURGICAL VALVE REPLACEMENT Tissue Valve for Aortic and Mitral Valve Replacement ARE MEDTRONIC SURGICAL TISSUE HEART VALVES RIGHT FOR YOU? Medtronic surgical heart valves are for
More informationMitral Valve Surgery: Lessons from New York State
Mitral Valve Surgery: Lessons from New York State Joanna Chikwe, MD Professor of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai Chairman & Program Director Department of Cardiovascular
More informationThe Last Generation of Pericardial Valves in the Aortic Position: Ten-Year Follow-up in 589 Patients
The Last Generation of Pericardial Valves in the Aortic Position: Ten-Year Follow-up in 589 Patients Michel R. Aupart, MD, Agnes L. Sirinelli, MD, Frank F. Diemont, MD, Yvon A. Meurisse, MD, Xavier B.
More informationTissue vs Mechanical What s the Data??
Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William
More informationCONTRIBUTION. Aortic valve replacement in young patients: long-term follow-up
CONTRIBUTION Aortic valve replacement in young patients: long-term follow-up DOUGLAS S. MOODIE, MD; USAMA HANHAN, MD; RICHARD STERBA, MD; DANIEL J. MURPHY, Jr, MD; ELIOT R. ROSENKRANZ, MD; ANDREA M. KOVACS,
More informationLong-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
J Korean Med Sci 2007; 22: 1060-4 ISSN 1011-8934 DOI: 10.3346/jkms.2007.22.6.1060 Copyright The Korean Academy of Medical Sciences Long-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
More informationLONG-TERM RESULTS OF HEART VALVE REPLACEMENT WITH THE EDWARDS DUROMEDICS BILEAFLET PROSTHESIS: A PROSPECTIVE TEN-YEAR CLINICAL FOLLOW-UP
LONG-TERM RESULTS OF HEART VALVE REPLACEMENT WITH THE EDWARDS DUROMEDICS BILEAFLET PROSTHESIS: A PROSPECTIVE TEN-YEAR CLINICAL FOLLOW-UP Bruno K. Podesser, MD a Gudrun Khuenl-Brady, MD a Ernst Eigenbauer,
More informationKinsing Ko, Thom de Kroon, Najim Kaoui, Bart van Putte, Nabil Saouti. St. Antonius Hospital, Nieuwegein, The Netherlands
Minimal Invasive Mitral Valve Surgery After Previous Sternotomy Without Aortic Clamping: Short- and Long Term Results of a Single Surgeon Single Institution Kinsing Ko, Thom de Kroon, Najim Kaoui, Bart
More informationOn October 3, 1977, the first St. Jude Medical (SJM)
The St. Jude Medical Cardiac Valve Prosthesis: A 25-Year Experience With Single Valve Replacement Robert W. Emery, MD, Christopher C. Krogh, Kit V. Arom, MD, PhD, Ann M. Emery, RN, Kathy Benyo-Albrecht,
More informationMIDTERM RESULTS AFTER AORTIC VALVE REPLACEMENT WITH FREEHAND STENTLESS XENOGRAFTS: A COMPARISON OF THREE PROSTHESES
MIDTERM RESULTS AFTER AORTIC VALVE REPLACEMENT WITH FREEHAND STENTLESS XENOGRAFTS: A COMPARISON OF THREE PROSTHESES Giovanni Battista Luciani, MD Paolo Bertolini, MD Barbara Vecchi, MD Alessandro Mazzucco,
More informationBiological or mechanical valve prosthesis?
XXIX Giornate Cardiologiche Torinesi ADVANCES IN CARDIAC ARRHYTHMIAS AND GREAT INNOVATIONS IN CARDIOLOGY Turin, October 27-28, 2017 Centro Congressi Unione Industriale WHAT HAS CHANGED IN CARDIAC SURGERY?
More information164 Ann Thorac Surg 45: , Feb Copyright by The Society of Thoracic Surgeons
Heart Valve Replacement with the Bjork-Shiley Mbnostrut Valve: Early Results of a Multicenter Clinical Investigation Lars I. Thulin, M.D., William H. Bain, F.R.C.S., Hans H. Huysmans, M.D., Gerrit van
More informationThe CarboMedics prosthetic valve (Sulzer CarboMedics,
Long-Term Result of 1144 CarboMedics Mechanical Valve Implantations Chang Hyun Kang, MD, Hyuk Ahn, MD, Kyung Hwan Kim, MD, and Ki-Bong Kim, MD Department of Thoracic and Cardiovascular Surgery, Seoul National
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/28521 holds various files of this Leiden University dissertation Author: Katsanos, Spyridon Title: Outcomes of transcatheter aortic valve implantation Issue
More information